Even though the high cost of medication in Chron Disease (CD), monoclonal antibodies represent a major advance in therapy with significant decrease hospitalizations, surgery and laboratory tests numbers. Also, they have a higher effectiveness compared to conventional therapy 1, 2 . The last publication related to cost minimization analysis of adalimumab (ADA) and infliximab (IFX) -2009 -was based on weight range and only medication costs 3 .
RESULTS
This study aim study was to describe the total treatment costs related to Crohn's Disease treatment with biologics and to evaluate these costs based on the most prevalent weight range. 5 year time period.
The median patient weight used in this analysis was 68±4,08kg (Weight range: 64 to 72kg -normal distribution). For IFX the Medication Cost was R$92.478,12, Application Cost was R$2.360,33 and the Total Treatment Cost was R$94.838,45. For ADA the Medication Cost was R$85.807,15, Application Cost was R$3.788,98 and the Total Treatment Cost was R$89.596,13 - Table 2 . Figure 2 present the treatment costs related to the length of disease, with ADA the costs were stable and with IFX they progressively grow. Comparing the scenario with IFX and ADA, the treatment with ADA presented savings of R$5.242,32 per patient/year - Figure 1 . The weight interval cost analysis presented savings of R$5.242,32per patient/year for ADA in a range of 64 to 72kg. In sensitivity analysis ADA presented economic savings in most scenarios, the variation of IFX vial cost and ADA syringe costs are important factors that could modify the model results.
The treatment of CD with ADA compared to IFX presented economic savings for nearly 68% of patients with CD in the Brazilian Private HealthCare System. AbbVie Inc. funded the study. AbbVie was responsible for the study design, research, analysis, data collection, interpretation of data, and writing, reviewing, and approving of the publication. The authors would like to thank Vinicius Vitale from AbbVie for modelling support.
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Figure 2: Costs according the lenght of disease (R$).
METHODS
A cost-minimization analysis was performed among Adalimumab -subcutaneous (ADA) and Infliximabintravenous (IFX) to compare the total treatment costs in Crohn's disease according to the Brazilian Private HealthCare System perspective. Drug prices were based on Factory Prices plus 18% taxes (CMED source) - Table 1 . Total treatment cost was calculated based on the dose per application, number of vial/syringe, cost of application and median and range of weight (Table 2) . Yearly treatment cost was calculated for patients with a median of 68kg, according to doses defined in product labels. A cost analysis for a weight range was performed. A univariate analysis was performed to determine the impact on results. 
RESULTS
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OBJECTIVE:
The aim of this study was to describe the total treatment costs related to Crohn's Disease treatment with biologics and to evaluate these costs based on the most prevalent weight range. METHODS: A cost-minimization analysis was performed among adalimumab-subcutaneous (ADA) and infliximab-intravenous (IFX) to compare the total treatment costs in Crohn's disease according to the Brazilian Private HealthCare System perspective. Total treatment cost was calculated based on the dose per application, number of vial/syringe, cost of application and median and range of weight. These inputs were based on scientific literature. Yearly treatment cost was calculated for patients with a median of 68kg, according to doses defined in product labels. A cost analysis for a weight range was performed. Drug prices were based on Factory Prices plus 18% taxes (CMED source). An univariate analysis was performed to determine the impact on results.
RESULTS:
The median patient weight used in this analysis was 68±4,08kg (Weight range: 64 to 72kg -normal distribution). The median patient weight used in this analysis was 68±4,08kg (Weight range: 64 to 72kg -normal distribution) with a disease length of 72 months 9 . Study limitations: we assume the same model of reimbursement between HMOs for all the market; the population growth rate that was used had base just in the population that use the Private Health Care System; variation in costs of infusion and application. 
